Isolation and Characterization of a Clinically-Derived Staphylococcus epidermidis HE23: Revealing Its Antibiotic Resistome and Metabolic Potential

Inside the warm, humid cradle of a neonatal incubator, a delicate balance is maintained to help premature infants adapt to the world outside the womb. These machines are life-saving, yet they also create a unique environment where bacteria can thrive. While many people think of bacteria as invaders that must be kept out, the reality is more complex. Some microbes live harmlessly on our skin, but when they find their way into a hospital setting, especially around vulnerable newborns, they can become dangerous. A specific type of bacteria, known as Staphylococcus epidermidis, is a common resident on human skin. Usually, it is a harmless neighbor, but in the hands of a sick infant, it can turn into a serious threat, causing infections that are difficult to treat because the bacteria have learned to resist the medicines doctors use to kill them.

Scientists have long known that hospital equipment can harbor these resistant bacteria, but the exact genetic secrets that allow them to survive and spread in such environments are still being uncovered. Understanding these secrets is crucial because it helps doctors figure out how to stop infections before they start. If a bacterium can survive the harsh chemicals used to clean a hospital room, or if it can hide inside the plastic walls of an incubator, it poses a constant risk to the most fragile patients. The question is not just whether these bacteria are present, but what specific tools they carry in their genetic code that make them so hard to defeat.

A team of researchers from Anhui Medical University and the Lu'an Center for Disease Control and Prevention decided to look closely at one such bacterium found in a neonatal incubator. They collected a sample from the inner wall of a machine that had been in continuous use for two weeks, despite being cleaned twice a day with hydrogen peroxide and ultraviolet light. From this sample, they isolated a single strain of bacteria, which they named HE23. To understand exactly what this bacterium was and how it survived, the scientists did not just look at it under a microscope; they read its entire genetic instruction manual, a process called whole-genome sequencing. They also analyzed the chemical substances the bacterium produced to see what it was capable of making.

The results of this deep dive revealed that HE23 is a complete and self-contained organism with a circular chromosome and two smaller rings of DNA called plasmids. The researchers found that this bacterium carries a dangerous arsenal of nine different genes that help it resist antibiotics. Some of these genes are located on the main chromosome, while others are on the plasmids, which act like portable toolkits that can be shared with other bacteria. Among these tools are genes that protect the bacteria from a major class of drugs called beta-lactams, which includes penicillin and methicillin. The study confirmed that HE23 is indeed resistant to these drugs, as well as to a group of medicines called quinolones, based on antimicrobial susceptibility testing that measured the minimum concentration of antibiotics needed to inhibit the bacteria's growth.

What makes this discovery particularly concerning is the combination of resistance factors. The bacteria carry a gene called mupA on one of its plasmids, which helps it resist a specific antibiotic often used to treat skin infections. At the same time, it has other genes on its main chromosome that protect it from beta-lactams. This mix suggests that the bacterium is highly adaptable and could easily pass these resistance traits to other bacteria it encounters. The researchers also found genes that help the bacteria defend themselves against natural antimicrobial peptides, which are part of the human body's first line of defense. This suggests the bacterium may be equipped to survive not just in a bottle of medicine, but also inside a human body.

Beyond its ability to resist drugs, the study looked at what the bacterium actually produces. Using a technique called metabolomics, the scientists analyzed the chemical soup surrounding the bacteria. They found that HE23 produces several secondary metabolites, which are complex chemicals that bacteria make to help them survive or compete. Among these were substances that were putatively annotated as harmaline and cinobufagin. Harmaline is a compound known to affect the nervous system, while cinobufagin is a toxic substance found in toad skin that has been used in traditional medicine but can be poisonous in high doses. The presence of these chemicals suggests that the bacterium might be capable of producing toxins that could worsen an infection in a newborn, adding another layer of danger to its presence in an incubator.

The researchers also compared the genetic code of HE23 with other known strains of the same bacteria to see how it fits into the bigger picture. They found that while HE23 is very similar to other strains, it has unique genetic rearrangements and 15 specific protein clusters that set it apart. These specific features suggest that the bacterium has evolved specifically to survive in the hospital environment. It appears to have adapted to the stress of being cleaned and the competition for nutrients in a way that makes it a persistent resident of the incubator. The study highlights that even though the incubator is cleaned regularly, this bacterium can still find a way to stay and potentially spread.

The findings of this research paint a clear picture of a bacterium that is well-equipped to cause trouble in a neonatal intensive care unit. It is not just a passive passenger; it is an active survivor with a genetic toolkit that includes resistance to multiple drugs and the ability to produce potentially harmful chemicals. The fact that this strain was found on a high-touch surface of an incubator that undergoes daily disinfection is a strong warning sign. It suggests that current cleaning methods might not be enough to eliminate these tough bacteria from the environment where they pose the greatest risk.

This study does not claim to have solved the problem of neonatal infections, but it provides a detailed map of one specific threat. By identifying the exact genes and chemicals involved, the researchers have given doctors and hospital staff a better understanding of what they are up against. The presence of these resistance genes and toxic metabolites in a strain isolated from an incubator underscores the need for stricter monitoring and more targeted infection control strategies. It serves as a reminder that in the fight to protect newborns, understanding the microscopic world is just as important as the medical care provided to the infants themselves. The work suggests that future efforts must focus on how these bacteria move their resistance genes around and how their toxic products interact with the developing immune systems of premature babies.